1. Food-effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden.
- Author
-
Boons CCLM, den Hartog YM, Janssen JJWM, Zandvliet AS, Vos RM, Swart EL, Hendrikse NH, and Hugtenburg JG
- Subjects
- Adult, Aged, Area Under Curve, Drug Administration Schedule, Fasting, Female, Humans, Male, Middle Aged, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors pharmacokinetics, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrimidines pharmacokinetics, Quality of Life, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive therapy, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use
- Abstract
Objectives: Taking advantage of its food-dependent bioavailability, the present study investigated the effect of a reduced dose taken with real-life meals on the pharmacokinetics (PK) of nilotinib in chronic myeloid leukaemia (CML) patients., Methods: Nilotinib was taken fasted (300 mg BID, days 1-4) or with real-life meals (200 mg BID, days 5-11). Rich sampling (days 1, 3, 8, 11) allowed for non-compartmental PK analysis. Nilotinib exposure (AUC
0-12 h -Cmin -Cmax ) and its intra- and interpatient variability were compared between the two regimens. Adverse events were recorded by means of a patient diary and ECG monitoring., Results: Fifteen patients aged 40-74 years participated. Nilotinib PK following 200 mg BID taken with a meal strongly resembled that of 300 mg BID taken fasted (Cmin percentile (P)10-P90: 665-1404 ng/mL and 557-1743 ng/mL, respectively). Meals delayed nilotinib absorption. Intra- and interpatient variability were not increased by intake with meals. Nilotinib with food was well tolerated., Conclusion: With support of therapeutic drug monitoring, the use of a reduced 200 mg nilotinib dose with real-life meals seems feasible and safe. Future (confirmatory) studies should further explore the usefulness of nilotinib dosing together with food, including the relationship with treatment efficacy as well as long-term effects on quality of life., Clinical Trial Registration: NTR5000 (Netherlands Trial Register, www.trialregister.nl)., (© 2020 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)- Published
- 2020
- Full Text
- View/download PDF